Stock Analysis

Hofseth BioCare Second Quarter 2024 Earnings: kr0.04 loss per share (vs kr0.015 profit in 2Q 2023)

OB:HBC
Source: Shutterstock

Hofseth BioCare (OB:HBC) Second Quarter 2024 Results

Key Financial Results

  • Revenue: kr80.4m (up 5.2% from 2Q 2023).
  • Net loss: kr17.6m (down by 405% from kr5.76m profit in 2Q 2023).
  • kr0.04 loss per share (down from kr0.015 profit in 2Q 2023).
earnings-and-revenue-history
OB:HBC Earnings and Revenue History August 25th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hofseth BioCare shares are up 8.1% from a week ago.

Risk Analysis

It is worth noting though that we have found 3 warning signs for Hofseth BioCare (2 are concerning!) that you need to take into consideration.

Valuation is complex, but we're here to simplify it.

Discover if Hofseth BioCare might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.